Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
People
Adjust height of sidebar
KMap
Profile
Fariba Donovan
Associate Professor, BIO5 Institute | Member of the Graduate Faculty | Associate Professor, Medicine
Medicine
Full Page
Overview
Research
More
Collaboration
(28)
Mindy Fain
Mutual work: 1 Proposal
Collaboration Details
H-H. Sherry Chow
Mutual work: 1 Proposal
Collaboration Details
Kenneth Knox
Mutual work: 3 Proposals﹒1 Grant
Collaboration Details
Jarrod Mosier
Mutual work: 2 Proposals
Collaboration Details
Patrick Wightman
Mutual work: 1 Grant﹒1 Proposal
Collaboration Details
Page 1 of 6
Previous page
Next page
Grants
(9)
Development of Coccidioides Cytokine Release Assay
Active
·
2024
·
$349.5K / $249.6K
·
External
Co-Investigator (COI)
coccidioides,
cytokine,
assay,
development,
coccidioidomycosis
Rapid Immunoassay for Diagnosis of Coccidioidomycosis
Active
·
2022
·
$92.4K / $184.7K
·
External
Co-Investigator (COI)
diagnostic methods,
infectious diseases,
immunoassay,
fungal infections,
rapid testing
An Observational Study to Assess the Prevalence and Outcomes of Primary Pulmonary Coccidioidomycosis in Persons Aged >14 years Presenting with Community Acquired Pneumonia (CAP) in Endemic Areas
Active
·
2019
·
$247.3K / $650.7K
·
External
Co-Investigator (COI)
pulmonary infections,
epidemiology,
respiratory diseases,
public health,
clinical research
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting with Community Acquired...
Active
·
2019
·
$225.5K / $593.4K
·
External
Co-Investigator (COI)
clinical trials,
fungal infections,
antifungal medications,
pneumonia,
community-acquired infections
An Open-label Single-arm Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections due to Lomentospora prolificans, Scedosporium spp., Aspergillus spp., and other Resistant Fungi in Patien
2021
·
$2.5M
·
External
Principal Investigator (PI)
fungal infections,
antifungal treatment,
invasive mycoses,
resistant fungi
Page 1 of 2
Previous page
Next page
Publications
(34)
Recent
Controversies in the Management of Central Nervous System Coccidioidomycosis
2022
infectious diseases,
central nervous system,
management,
coccidioidomycosis,
controversies
Immunogenetics associated with severe coccidioidomycosis
2022
immunogenetics,
coccidioidomycosis,
severe,
immunology,
infectious diseases
Contribution of Biologic Response Modifiers to the Risk of Coccidioidomycosis Severity.
2022
biologic response modifiers,
coccidioidomycosis severity,
contribution,
risk,
biologic modifiers
Clinical Predictors of Coccidioidomycosis from a Cross-Sectional Study
2022
clinical predictors,
coccidioidomycosis,
clinical research,
infectious diseases
Endemic Mycoses: Better Diagnosis and Reporting Needed
2022
mycoses,
diagnostic methods,
epidemiology,
public health,
infectious diseases
Cutaneous Leishmaniasis Caused by an Unknown Leishmania Strain, Arizona, USA
2021
leishmaniasis,
infectious diseases,
parasitology,
epidemiology,
public health
TNF Blockade Inhibits Both Initial and Continued Control of Pulmonary Coccidioides.
2021
immunology,
infectious diseases,
respiratory health,
pulmonary mycosis,
drug therapy
A randomized, double-blind, placebo-controlled clinical trial of fluconazole as early empiric treatment of coccidioidomycosis pneumonia Valley Fever) in adults presenting with community-acquired pneumonia in endemic areas FLEET-Valley Fever)
2021
clinical trial,
antifungal treatment,
pneumonia,
coccidioidomycosis,
empiric treatment
Automated Biomedical Lexicon Creation with Graph Search for Word Embeddings
2021
biomedical,
lexicon,
graph search,
word embeddings,
automated
Contribution of Biologic Response Modifiers to the Risk of Coccidioidomycosis Severity
2021
biologic response modifiers,
coccidioidomycosis,
risk,
contribution,
severity